Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO).

6 Dec 2012

IL17RC-mediated immune responses can be crucial in causing AMD

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

29 Nov 2012

Macular pigment screener launched by Elektron Technology

Elektron Technology is launching a new, easy-to-use macular pigment screener (MPS II) that can quickly identify those most at risk of developing age-related macular degeneration (AMD).

28 Nov 2012

Carnosic acid promotes eye health

Herbs widely used throughout history in Asian and early European cultures have received renewed attention by Western medicine in recent years. Scientists are now isolating the active compounds in many medicinal herbs and documenting their antioxidant and anti-inflammatory activities. In a study published in the journal Investigative Ophthalmology & Visual Science, Stuart A. Lipton, M.D., Ph.D. and colleagues at Sanford-Burnham Medical Research Institute (Sanford-Burnham) report that carnosic acid, a component of the herb rosemary, promotes eye health.

28 Nov 2012

EC approves Regeneron’s EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).

27 Nov 2012

Simple, accurate testing protocol to determine driving fitness in individuals with MS

A simple, accurate testing protocol to determine driving fitness in individuals with multiple sclerosis is the aim of a three-year study at Georgia Health Sciences University.

21 Nov 2012

ACT announces results from three ongoing stem cell clinical trials for macular degeneration

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that its upcoming conference call on its third quarter financial results will also provide some representative examples of data being collected from patients in its clinical trials for forms of macular degeneration.

9 Nov 2012

Corneal limbal stromal cells could lead to new treatments for eye conditions

Eye experts and scientists at the University of Southampton have discovered specific cells in the eye which could lead to a new procedure to treat and cure blinding eye conditions.

8 Nov 2012

Targeted deletion of major VEGF gene in mice induces vision loss

Millions of people with "wet" macular degeneration are prescribed a class of medication known as anti-VEGF drugs. But now scientists at The Scripps Research Institute (TSRI) have found that a drastic reduction of VEGF activity may do more harm than good.

26 Oct 2012

Scientists create yellow potatoes with high carotenoid levels

Potatoes with higher levels of beneficial carotenoids are the result of U.S. Department of Agriculture (USDA) studies to improve one of America's most popular vegetables.

26 Oct 2012

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) on Sat., Nov. 10, 2012 at 9:15 a.m.

25 Oct 2012

Ranibizumab improves driving prospects for AMD patients

Treatment with ranibizumab can preserve and even improve the perceived driving ability of patients with age-related macular degeneration, show the results of two randomized trials.

10 Oct 2012

NACA could prevent or cure cataracts, macular degeneration and other eye conditions

Researchers at Missouri University of Science and Technology are working with an antioxidant that could prevent or cure cataracts, macular degeneration and other degenerative eye disorders.

10 Oct 2012

Ranibizumab injections keep those with AMD driving longer

The advanced neovascular, or “wet,” form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But results of a new study, published in the online version of the journal Ophthalmology, suggest that monthly injections of ranibizumab improve eye chart test results required for a driver’s license, build driver confidence and keep those with AMD driving longer.

3 Oct 2012

Experimental stem cell treatment improves vision in blind mice

An experimental treatment for blindness, developed from a patient's skin cells, improved the vision of blind mice in a study conducted by Columbia ophthalmologists and stem cell researchers.

3 Oct 2012

Galectin-1 drives growth of Kaposi sarcoma tumors

A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.

2 Oct 2012

Level of vision, not gain in letters seen, marks success of AMD treatment

The number of patients with a particular level of vision may be a better mark of the success of treatment for neovascular age-related macular degeneration than the gain or loss of letters able to be seen in logMAR chart testing, suggest researchers.

1 Oct 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Cost of glaucoma revealed

The first 6 months after an open-angle glaucoma diagnosis are the most costly within the first 2 years of having the condition, report US researchers.

26 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012